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ABSTRACT
We have previously shown that amotosalen HCl (S-59 psoralen)–treated donor splenocytes, which have limited
proliferative capacity in vitro, can protect major histocompatibility complex–mismatched bone marrow trans-
plant (BMT) recipients from lethal murine cytomegalovirus infection without causing graft-versus-host
disease. In this study, we further investigated the effects of amotosalen-treated donor T cells on immune
reconstitution after allogeneic BMT. We were surprised to find that amotosalen-treated donor T cells
persisted long-term in vivo, comprising 6% to 10% on average of the T-cell compartment of transplant
recipients at 4 months after transplantation. Donor T cells derived from amotosalen-treated splenocytes were
predominantly polyclonal CD44hi/int CD8 memory T cells and were functionally active, synthesizing inter-
feron  in response to stimulation with murine cytomegalovirus antigen. Amotosalen-treated donor T cells,
reisolated from BMT recipients’ spleens >4 months after transplantation, proliferated in vitro, thus indicating
repair of amotosalen-mediated DNA cross-links. Compared with infusion of untreated donor splenocytes,
amotosalen-treated cells enhanced thymopoiesis by bone marrow–derived stem cells in BMT recipients.
However, amotosalen treatment abrogated the thymopoietic activity of lymphoid progenitor cells among the
donor splenocytes. Thus, infusion of amotosalen-treated donor T cells produced rapid immune reconstitution
after major histocompatibility complex–mismatched BMT by transferring long-lived polyclonal memory
T cells with antiviral activity and also by enhancing bone marrow–derived thymopoiesis. This is a novel
approach to adoptive immunotherapy in allogeneic BMT.
© 2005 American Society for Blood and Marrow Transplantation
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aNTRODUCTION
The therapeutic potential of allogeneic bone
arrow transplantation (BMT) and hematopoietic
rogenitor cell transplantation for treatment of ma-
ignant diseases relates both to the effect of the
hemoradiotherapy used during conditioning and to
he graft-versus-leukemia activity of donor T and
atural killer lymphocytes [1-3]. However, graft-
ersus-host disease (GVHD) is a major complica- p
B&MTion after allogeneic BMT that limits the overall
uccess of the procedure. Efforts have been made to
educe the GVHD activity of allogeneic BMT by
epleting donor T cells from the graft. However,
his approach results in delayed immune reconsti-
ution, which leads to opportunistic infections such
s cytomegalovirus (CMV) and aspergillus, as well
s the loss of graft-versus-leukemia effects, and this
redisposes to leukemia relapse [4,5].
169
c
a
d
h
p
t
a
d
m
i
e
e
a
t
r
t
t
t
a
p
r
m
i
n
v
w
g
r
a
w
c
t
s
m
m
C
[
e
i
B
t
p
e
w
m
o
e
r
r
T
c
r
A
c
[
s
s
t
a
T
t
g
M
M
T
H
g
H
t
S
E
C
b
a
P
A
d
u
t
S
c
f
1

s
5
d
s
b
s
i
p
a
w
3
f
t
a
w
u
d
t
v
t
M. S. Hossain et al.
1A signiﬁcant number of hematopoietic progenitor
ell transplant recipients experience CMV infection
nd develop CMV pneumonitis, a fatal clinical syn-
rome in many affected patients [6]. Drug-resistant
erpes simplex infections are also an increasing
roblem among allogeneic BMT patients [7], and
his further highlights the need for more effective
ntiviral therapeutic approaches after BMT. Using
onor T cells with antiviral activity for adoptive im-
unotherapy is a powerful approach to accelerate
mmune reconstitution after transplantation; however,
xisting methods involving the isolation and in vitro
xpansion of antiviral T-cell clones are labor intensive
nd have not been widely applied to clinical transplan-
ation [8]. Hence, we have focused on developing
apid approaches to pretreat bulk polyclonal popula-
ions of donor T cells to reduce their GVHD poten-
ial while preserving their antiviral activity [9].
Recent studies have demonstrated the therapeu-
ic potential of donor T cells treated ex vivo with
motosalen HCl, a novel synthetic psoralen com-
ound that is photoactivated by UV-A light and
eacts with pyrimidine bases to form covalent DNA
onoadducts; DNA then cross-links, thus prevent-
ng DNA replication [10]. Amotosalen-treated do-
or T cells lack signiﬁcant proliferative capacity in
itro [11-13]. When transplanted in combination
ith T cell–depleted (TCD) bone marrow (BM)
rafts, pretreated donor T cells suppress allograft
ejection and improve survival without causing
cute GVHD [14-16]. It is important to note that
e have shown that amotosalen-treated donor T
ells also rapidly reconstitute antiviral immunity in
ransplant recipients. Infusion of pretreated donor
plenocytes at the time of transplantation protects
urine major histocompatibility complex (MHC)–
ismatched BMT recipients from lethal murine
MV (mCMV) infection without causing GVHD
17].
The work presented herein was undertaken to
valuate the effects of pretreated T cells on long-term
mmune reconstitution in survivors of allogeneic
MT. We initially hypothesized that amotosalen-
reated donor T cells would persist for only a short
eriod after infusion into BMT recipients. Unexpect-
dly, we found that amotosalen-treated donor T cells
ith a memory phenotype persisted for at least 4
onths in vivo. By studying the functional properties
f these donor T cells reisolated from BMT recipi-
nts, we found that amotosalen-treated donor T cells
etained the ability to express interferon (IFN)– in
esponse to mCMV antigen. Even though pretreated
cells did not produce detectable GVHD, surviving
ells had regained the ability to proliferate in vitro in
esponse to mCMV antigen or anti-CD3 stimulation.
dditionally, donor BM–derived thymopoiesis, a pro-
ess that is particularly sensitive to ongoing GVHD s
7018], was enhanced in recipients of amotosalen-treated
plenocytes as compared with recipients of untreated
plenocytes. These data, therefore, demonstrate that
his novel form of immunotherapy rapidly improves
ntiviral immunity by transferring polyclonal memory
cells and enhances long-term immune reconstitu-
ion by supporting BM-derived thymopoiesis in allo-
eneic BMT recipients.
ATERIALS AND METHODS
ice
CB6F1 (C57BL/6  BALB/c; H-2b/d, CD45.2/
hy1.2) mice and PepBoy (B6.SJL-PtprcaPep3b/BoyJ;
-2b, CD45.1/Thy1.2) mice on the C57BL/6 back-
round were obtained from Jackson Laboratories (Bar
arbor, ME). BA mice (H-2b, CD45.2/Thy1.1) on
he C57BL/6 background (Dr. Miriam Lieberman,
tanford University, Stanford, CA) were bred at
mory. Procedures conformed to the Guide for the
are and Use of Laboratory Animals and were approved
y the Emory University Institutional Animal Care
nd Use Committee.
reparation of Lymphocytes for
doptive Immunotherapy
Immune splenocytes were harvested from PepBoy
onors previously inoculated with 105 plaque-forming
nits of mCMV (Smith strain; American Type Cul-
ure Collection, Manassas, VA) 2 to 4 months earlier.
plenocytes were cultured at 107 cells per milliliter in
omplete media (RPMI plus 10% heat-inactivated
etal bovine serum, 1 mmol/L sodium pyruvate,
mmol/L nonessential amino acids, 50 mmol/L
-mercaptoethanol, 100 U/mL penicillin, 100 mg/mL
treptomycin, and 29 mg/mL l-glutamine) at 37°C in
% CO2 for 24 hours according to our previously
escribed methods [17]. The cultured cells were re-
uspended at 20  106 per milliliter of phosphate-
uffered saline with 5% heat-inactivated fetal bovine
erum (HyClone Laboratories, Logan, UT) contain-
ng 2 nmol/L amotosalen (S-59 psoralen; Cerus Cor-
oration, Concord, CA). A 25-mL total volume was
dded per 75-cm2 tissue culture ﬂask, and the cells
ere illuminated with UV-A light (320-400 nm;
.0 J/cm2 UV-A dose; Cole Parmer, Vernon Hills, IL)
or a total of 5 minutes divided into 2.5-minute frac-
ions separated by a 1- to 2-minute period of gentle
gitation. Treated cells were washed, and live cells
ere counted again under ﬂuorescence microscopy by
sing ethidium bromide mixed with acridine orange
ye [19]. The viability was usually 80% after pho-
ochemical treatment, and an appropriate dosage of
iable nucleated cells was used for adoptive immuno-
herapy. Cells cultured for 24 hours without amoto-
alen treatment were used as controls.
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Effects of Amotosalen-Treated T Cells In Vivo
Brradiation, Cell Transfer, and mCMV Infection of
MT Recipients
On day 1, CB6F1 mice received a total of 11 Gy
f irradiation divided into 2 doses (5.5 Gy each) 3
ours apart [9]. The following day, BM was ﬂushed
rom femurs and tibiae of naive BA donor mice, and
D3 T cells were depleted as previously described
9]. A total of 5  106 TCD BM cells were then
ransplanted alone or with different doses (ie, 1 106,
 106, 10 106, or 30 106) of amotosalen-treated
r untreated (culture only) donor splenocytes via tail
ein injection into irradiated CB6F1 recipient mice.
wo hours later, recipient mice were infected intraperi-
oneally with 5 104 plaque-forming units of mCMVor
ehicle. The development of clinical GVHD was mon-
tored twice weekly by weight loss and clinical signs of
air loss, rufﬂed fur, diarrhea, and decreased activity
9]. Moribund mice were killed and considered to have
ied on the day after death for analysis of posttrans-
lantation survival.
ymphocyte Isolation
Splenocytes and thymocytes were harvested from
MT recipients by gently crushing tissue between
rosted glass slides (Fisher Scientiﬁc, Pittsburgh, PA).
ingle-cell suspensions were prepared by passing the
esulting cell suspension through a cell strainer (BD
iosciences, San Jose, CA). Live lymphocytes were
uantitated by ﬂuorescence microscopy.
-Cell Proliferation
To measure mCMV peptide–speciﬁc prolifera-
ion, 100 000 splenocytes were cultured in 96-well
at-bottomed tissue culture plates with an equal
umber of irradiated (100 Gy) EL-4 cells previously
oaded with the mCMV early peptide HGIRNASFI
20] for 1 hour. After 4 days, cells were pulsed with
Ci of [3H]thymidine and harvested 16 to 18
ours later, and [3H]thymidine incorporation was
easured. To measure proliferation in response to
D3 cross-linking by plate-bound anti-CD3 mono-
lonal antibody (mAb; clone 145 2C11, functional
rade; eBioscience, San Diego, CA), the antibody
as diluted with phosphate-buffered saline to a con-
entration of 10 g/mL and used to coat 96-well
at-bottomed tissue culture plates overnight at 4°C.
D45.1 cells were sorted (99% purity) from total
plenocytes by using a FACSVantage (BD Bio-
ciences, San Jose, CA). A total of 100 000 CD45.1
ells in 0.2 mL of complete media were added to
nti-CD3–coated wells and incubated for 4 days at
7°C in 5% CO2. Positive controls were splenocytes
arvested from stably engrafted recipients of TCD
M plus 1  106 nontreated splenocytes, and cells
ultured in uncoated wells served as negative controls. 3
B&MTroliferation was measured as previously described
21].
low Cytometry
Flow cytometry was performed as previously
escribed [9]. The origin of CD8 and CD4 T
ells in BMT recipients was determined by staining
ith mAbs speciﬁc for donor BM (Thy1.1), donor
pleen (CD45.1), or host T cells (CD45.2 and
hy1.2) in combination with mAbs to CD8 and
D4. V T-cell receptor (TCR) expression on do-
or splenic CD8 and CD4 T cells was deter-
ined by staining with ﬂuorescein isothiocyanate–
onjugated mAbs to 15 V TCR isotypes (V2, 3, 4,
.1/5.2, 6, 7, 8.1/8.2, 8.3, 9, 10b, 11, 12, 13, 14, and
7a) in combination with CD45.1 phycoerythrin,
D8	 peridinin chlorophyll protein, and CD4 allophy-
ocyanin (APC). Anti-mCMV–speciﬁc CD8 T cells
ere quantitated by using an APC-conjugated HGIR-
ASFI/H-2Db tetramer (NIAID Tetramer Core Fa-
ility, Atlanta, GA) [20] and by intracellular cytokine
taining (ICS). For ICS, surface-stained cells were
ermeabilized and ﬁxed according to the manufactur-
r’s instructions (Cytoﬁx/Cytoperm; BD Biosciences,
an Diego, CA) and then incubated with a mAb
gainst IFN-. For quantitation of donor spleen–de-
ived memory and naive CD8 T cells, cells were
tained with mAbs for CD44 (ﬂuorescein isothiocyanate)
nd CD62L (biotin-streptavidin APC), respectively,
long with mAbs for CD45.1 (phycoerythrin) and
D8	 (peridinin chlorophyll protein). Isotype-
atched antibodies were used as controls. Stained
ells were analyzed on a FACSort instrument (BD
iosciences, San Jose, CA) by using Cell Quest soft-
are. All antibodies were obtained from BD Bio-
ciences Pharmingen (San Diego, CA).
tatistical Analyses
The Student t test was applied as described with
ifferences considered signiﬁcant when P 
 .05.
ESULTS
herapeutic Effectiveness of Amotosalen-Treated
llogeneic Donor Splenocytes
By using the parental 3 F1 model of MHC-
ismatched BMT, TCD BM from the C57BL/6
ongenic strain BA (CD45.2Thy1.1) was trans-
lanted with graded doses (1  106, 3  106, 10 
06, or 30  106) of splenocytes from mCMV-
mmune PepBoy (CD45.1Thy1.2) mice. The
plenocytes were either amotosalen treated or un-
reated. Amotosalen-treated splenocytes effectively
revented mCMV lethality over a broad therapeutic
ange of cell doses. Recipients of 30  106, 10  106,
 106, and 1  106 pretreated splenocytes showed
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100%, 100%, 90%, and 40% survival to day 100
fter transplantation, respectively (Figure 1A). With
he exception of the fourth group, all mice gained
eight at approximately the same rate as control non–
CMV-infected BMT recipients (no splenocytes/no
CMV; Figure 1C). In contrast, recipients of 30 
06 untreated splenocytes, with or without concomi-
ant mCMV infection, experienced 80% mortality by
ay 40 (Figure 1B). In previous studies using this
odel, we conﬁrmed the antiviral activity of un-
reated splenocytes and showed that mortality in
his setting is due to GVHD [17]. Mice that under-
ent transplantation with 10  106 untreated
plenocytes also developed severe GVHD: only
0% survived to day 136. Recipients of 1 to 3  106
ntreated splenocytes developed transient nonlethal
VHD after transplantation, as manifested by a
apid 20% weight loss and subsequent recovery
Figure 1D). Other clinical signs of GVHD (de-
reased motion or activity, hunched back, and ruf-
ed fur) were consistent with the weight data (not
hown). All mCMV-infected recipients of TCD BM
lone died within 20 days of transplantation (not
hown), whereas all recipients of TCD BM without
plenocytes or mCMV infection survived to the
ermination of the experiment (no splenocytes/no
igure 1. Dose response of amotosalen-treated donor splenocytes
 106 (’), 10 106 (), or 30 106 () amotosalen-treated (A an
onors in combination with TCD BM from the naive BA donors.
laque-forming units of mCMV. Some groups received 30  106 s
and B, survival; C and D, weight change over the course of theCMV; Figure 1A). d
72ffects of Amotosalen-Treated T Cells on
ost-BMT Lymphoid Reconstitution
To investigate the effects of donor T cells on im-
une reconstitution, long-term-surviving BMT recipi-
nts were studied 4 months after transplantation. BMT
ice that received 3  106 or 10  106 amotosalen-
reated cells had an average of 140  39  106 and 117
38  106 nucleated cells per spleen, respectively,
oth of which were signiﬁcantly greater than the av-
rage 54  34  106 splenocytes in mice that received
 106 untreated cells (P 
 .05; Figure 2). Recipients
f 30  106 amotosalen-treated splenocytes, with and
ithout concomitant mCMV infection, had similar
umbers of splenocytes (92  28  106 and 96  49
106, respectively). Because amotosalen treatment
locks lymphocyte proliferation [17], it was unex-
ected that recipients of amotosalen-treated lympho-
ytes would have signiﬁcantly better splenic reconsti-
ution than recipients of untreated cells. Subsequent
tudies to investigate phenotypic and functional dif-
erences in lymphoid reconstitution between recipi-
nts of amotosalen-treated and untreated splenocytes
ocused on recipients of 3 106 or 10 106 amotosalen-
reated and 3 106 untreated splenocytes. Recipients of
arger numbers (10  106) of untreated splenocytes
geneic BMT. Irradiated F1 mice were injected with 1  106 (Œ),
untreated (B and D) splenocytes obtained from immunized PepBoy
ours after transplantation, recipients were infected with 5  104
ytes without mCMV infection (□) or 5  106 TCD BM only (●).in allo
d C) or
Two h
plenocied of GVHD or were severely lymphopenic.
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Effects of Amotosalen-Treated T Cells In Vivo
BSplenic T-cell chimerism was studied by ﬂuores-
ence-activated cell-sorting (FACS) analysis with anti-
odies speciﬁc for congenic surface markers (Table 1).
e were surprised to ﬁnd that amotosalen-treated and
ntreated T cells persisted to a similar extent in vivo.
here were no signiﬁcant differences in the absolute
umbers of donor splenocyte–derived CD3, CD8,
r CD4 T cells among mice that received 3 106 or
0  106 amotosalen-treated splenocytes or 3  106
ntreated splenocytes. Similar numbers were also seen
or recipients of 30  106 amotosalen-treated spleno-
ytes without mCMV infection. Likewise, there were
o differences in the numbers of residual host-derived
cells among these groups. However, the differences
n total splenocytes among groups seen in Figure 2
ould be accounted for by donor BM–derived lym-
hocytes. Recipients of amotosalen-treated donor
plenocytes and mCMV infection had 3 to 4 times
ore CD3, CD4, and CD8 T cells derived from
onor BM progenitors than did mCMV-infected re-
igure 2. Quantitation of nucleated cells in the spleens of BMT
ecipients. Splenocytes were harvested from recipients’ spleens 4
onths after BMT and mCMV infection and were counted by
sing ﬂuorescence microscopy. The mean absolute number (with
tandard error) of nucleated live cells per spleen in each group
n  5) is shown. Rx indicates amotosalen treated; Cx, untreated.
Student t test; P 
 .05 as compared with recipients of 3  106
ntreated splenocytes.
able 1. Splenic T-Cell Subsets from Transplant Recipients
Variable
Donor Spleen Derived
CD3 CD8 CD4 CD
x-10m  mCMV 3  1.2 2.4  0.6 0.6  0.5 27.7 
x-3m  mCMV 1.7  1.2 1.5  1.2 0.2  0.0 27.9 
x-3m  mCMV 2.5  1.2 2.2  1.1 0.4  0.1 7.7 
x-30m/no mCMV 2.5  1.8 1.4  0.9 1.0  0.9 13.1 
pleens were collected 4 months after transplantation, and CD3,
(CD45.1), donor BM (Thy1.2CD45.2), or the BMT recip
represent average per spleen  SD (106).Student t test; P 
 .05 (as compared between the amotosalen-treated and
B&MTipients of 3  106 untreated splenocytes (P 
 .05) or
CMV-negative recipients of 30  106 amotosalen-
reated splenocytes (P 
 .05). It is interesting to note
hat in all groups, donor splenocyte–derived T cells
ere predominantly (80%-90%) CD8, whereas do-
or BM–derived T cells were mainly (65%-70%)
D4. Thus, in the presence of mCMV infection,
ecipients of amotosalen-treated cells had better BM-
erived lymphoid reconstitution than recipients of un-
reated splenocytes.
ersisting Amotosalen-Treated Donor Splenic T
ells Retain a Polyclonal V TCR Repertoire
Because long-term survival of amotosalen-treated
cells was unexpected, we investigated the possibility
hat persisting T cells represented an oligoclonal ex-
ansion of a limited population of donor T cells that
scaped psoralen-mediated DNA cross-linking. TCR
 expression on donor splenocyte–derived T cells
as quantitated by FACS. CD8 (Figure 3) T cells
howed similar polyclonal V expression whether they
ere derived from amotosalen-treated (3 106 or 10
06) or untreated (3  106) splenocytes. TCR V
iversity was also similar to wild-type C57BL/6 mice
ith or without mCMV infection. These data indicate
hat persisting amotosalen-treated T cells are a diverse
olyclonal population.
ersisting Amotosalen-Treated CD8 T Cells Are
redominantly Memory Cells That Express IFN-
n Response to mCMV Antigen
At 4 months after transplantation, CD44 and
D62L expression was quantitated on CD45.1
D8 splenic T cells. The vast majority (90%-95%)
f CD8 T cells from mice that received adoptively
ransferred splenocytes and mCMV infection showed
right or intermediate staining intensity for CD44
CD44hi and CD44int cells, respectively, in right up-
er quadrants of Figure 4A). In contrast, approxi-
ately 80% of CD8 T cells were CD44hi/int in BMT
ice not infected with mCMV. Approximately 80%
f CD8 splenocytes from naive C57BL/6 mice were
lso CD44hi/int. Qualitative identiﬁcation of cells as
nor BM Derived Host Derived
CD8 CD4 CD3 CD8 CD4
9.3  4.5* 18.4  9.7* 0.1  0.1 0.1  0.1 0.0  0.0
8.4  2.9* 19.5  5.8* 1.5  1.5 0.7  0.7 0.8  0.7
2.6  1.4 5.1  4.6 0.1  0.0 0.1  0.1 0.1  0.0
4.7  4.2 8.4  6.1 0.2  0.1 0.1  0.1 0.1  0.1
and CD4 T-cell subpopulations derived from donor splenocytes
hy1.2CD45.2) were quantitated by FACS analysis. NumbersDo
3
14.2*
8.6*
6.1
10.2
CD8,
ient (Tuntreated groups).
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1D44hi, CD44int, or CD44low is dependent on gating.
o better quantify CD44 antigen expression, mean
uorescent intensities (MFIs) were determined for the
ajor populations of CD8 T cells in Figure 4A.
hereas the MFIs varied from 64.3 to 140.3 for BMT
ice, the MFI for CD44 staining of CD8 T cells
rom naive C57BL/6 mice was 46.3. Thus, these ﬁnd-
ngs indicate that CD8 T cells from BMT recipients
ave reproducibly higher levels of CD44 antigen on
heir surface than do CD8 T cells from naive
57BL/6 mice. The differences between groups were
ore impressive for CD62L expression (Figure 4B).
he vast majority of CD8 T cells in BMT mice that
eceived adoptive immunotherapy and infection were
D62Llow (all approximately 94%). In contrast, 26%
f cells were CD62Llow in the absence of mCMV
nfection, and only 10% of CD8 T cells were
D62Llow in naive C57BL/6 mice. Thus, donor
plenocyte–derived CD45.1 CD8 T cells are pre-
ominantly of the memory phenotype [22,23].
Anti-mCMV cytotoxic T lymphocytes (CTLs) de-
ived from donor splenocytes (CD45.1) were quan-
itated by both ICS and tetramer staining (Figure 4C).
solated splenocytes were stimulated in vitro by EL-4
ells loaded with the HGIRNASFI mCMV peptide
nd subsequently stained for CD45.1, CD8, and in-
racellular IFN- [20]. Unstimulated splenocytes were
tained with anti-CD8 and an H-2Db/HGIRNASFI
etramer. Similar numbers of splenocyte donor–
erived anti-mCMV CTLs were identiﬁed by both
echniques, with averages ranging from 1.0 to 3.5 
igure 3.Donor splenocyte–derived CD8T cells have diverse TC
ecipients (Rx-3m, Rx-10m, and Cx-3m) 4 months after transplantat
ice. Cells were stained with anti-TCR V mAbs along with mA
ecipients) and CD8. The percentages (mean  SD) of CD8 T c
D8 subsets represents approximately 70% of the total number
reated; Cx, untreated.04 cells per spleen. There were no signiﬁcant differ- n
74nces between mCMV-infected mice receiving amo-
osalen-treated (Rx) or untreated (Cx) splenocytes (P
.05). However, in the absence of mCMV infection in
ecipients of 30  106 (30m) Rx splenocytes, antiviral
TLs were present at signiﬁcantly lower levels (P 

05). Similar results were obtained for peripheral
lood lymphocytes (Figure 4D). Anti-mCMV CTLs
erived from the BM donor or BMT recipient were
nly rarely identiﬁed (not shown). When splenocytes
Figure 4E) or peripheral blood lymphocytes (Figure
F) from mCMV-infected BMT recipients were sub-
ected to antigen-nonspeciﬁc stimulation with phorbol
yristate acetate/ionomycin, there were once again sim-
lar numbers of CD45.1CD8 T cells expressing
FN-. Cell numbers were signiﬁcantly lower (P 

05) in the absence of mCMV infection (amotosalen-
reated-30m; Figure 4F). CD4 T cells were only rarely
FN- after phorbol myristate acetate/ionomycin stim-
lation (not shown). Thus, in mCMV-infected BMT
ecipients, persisting amotosalen-treated donor T
ells were primarily of the memory phenotype and
ere capable of expressing IFN- in response to viral
ntigen or nonspeciﬁc stimulation.
motosalen-Treated T Cells Regain Limited
roliferative Potential after Infusion
nto BMT Recipients
We previously reported that immediately after
reatment with amotosalen, T cells failed to prolifer-
te in vitro when stimulated with plate-bound anti-
D3 mAb [17]. Because we found that a substantial
epertoires. Splenocytes were harvested from mCMV-infected BMT
from mCMV-infected (60 days) or uninfected wild-type C57BL/6
inst CD45.1 (to select donor splenocyte–derived cells in BMT
ressing each TCR V subset are shown. The sum of all TCR V
lls. Five to 6 mice were used per group. Rx indicates amotosalenR V r
ion and
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Effects of Amotosalen-Treated T Cells In Vivo
Bor 4 months after transplantation, we investigated
hether they had repaired DNA cross-links and re-
ained the ability to proliferate. First, we reasoned
hat stimulation of CD8 T cells with HGIRNASFI
eptide should be relatively speciﬁc for HGIRNASFI/
-2Db tetramer–positive cells, which in BMT recip-
ents were found only among donor spleen–derived T
ells and not donor BM–derived or residual recipient
cells (Figure 5A). When splenocytes from BMT
ecipients were stimulated with mCMV peptide–loaded
rradiated EL-4 cells for 4 days, there was a signiﬁcant
eptide-speciﬁc proliferative response when compared
ith control cultures stimulated with EL-4 cells in the
bsence of peptide loading (Figure 5B). Proliferation of
plenocytes from recipients of amotosalen-treated donor
ells was comparable to proliferation of T cells from
ice that received cultured splenocytes. To unequivo-
igure 4. Surviving amotosalen-treated T cells are predominantly
plenocytes obtained from BMT recipient mice 4 months after tr
D45.1, CD3, CD8, CD44, and CD62L. Data from representative
r CD3 gated cells (for C57BL/6 mice) that stain with CD8 and/or
s the number (mean  SD) of IFN-CD8 T cells after stimulati
n the spleen (C) or peripheral blood (D). The numbers (mean  S
hown after stimulation with phorbol myristate acetate/ionomycin.ally demonstrate that the progeny of amotosalen- a
B&MTreated T cells regained proliferative capacity, we next
orted donor spleen–derived CD45.1 cells to 99%
urity (not shown) from mice that originally under-
ent transplantation with 30  106 amotosalen-
reated splenocytes 6 months earlier. The sorted cells
ere then stimulated with plate-bound anti-CD3
Ab for 4 days, and proliferation was compared with
hat of cells cultured in the absence of anti-CD3
Figure 5C). Unfractionated splenocytes from recipi-
nts of 1  106 untreated splenocytes were used as a
ositive control. The T-cell progeny of the amoto-
alen-treated splenocytes strongly proliferated in re-
ponse to anti-CD3 stimulation, as did untreated
plenocytes. The results of these studies show that
motosalen-treated T cells that survive long-term in
MT recipients regain the ability to proliferate in
esponse to stimulation through the TCR, which may
i memory T cells that produce IFN- in response to stimulation.
tation and naive C57BL/6 mice were stained with mAbs against
how the percentage of CD45.1 gated cells (from BMT recipients)
(A) and CD8 and/or CD62L (B). Antiviral T cells were quantitated
mCMV peptide or HGIRNASFI/H-2Db tetramerCD8 T cells
N-CD8 T cells in the spleen (E) and peripheral blood (F) are
6 mice were used per group.CD44h
ansplan
mice s
CD44
on with
D) of IFccount for their persistence [24,25].
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1motosalen-Treated T Cells Promote
M-Derived Thymopoiesis
Because recipients of amotosalen-treated T cells
howed signiﬁcantly better splenic lymphoid reconstitu-
ion by BM-derived T cells than recipients of untreated
plenocytes, we investigated whether similar effects
ould be seen in thymopoiesis. Thymocytes were iso-
ated from long-term-surviving BMT recipients, and T-
ell chimerism was studied by FACS analysis. Mice that
eceived 3 106 or 10 106 amotosalen-treated spleno-
ytes had an average of 50 106 cells per thymus, almost
ll of which (98%) were derived from the donor BM
Figure 6A). In contrast, in BMT mice that received 3
06 or 10  106 untreated splenocytes and had GVHD,
here were fewer total cells per thymus, and a higher
ercentage of thymocytes were derived from the spleno-
yte donor. In mice that received 30  106 amotosalen-
reated splenocytes without mCMV infection, essentially
ll thymocytes were derived from the donor BM. How-
ver, these mice had signiﬁcantly fewer total thymocytes
han the mCMV-infected recipients of treated spleno-
igure 5. In vitro proliferation of T cells derived from amotosa
arvested 4 months after transplantation and stained with mAbs for
plenocytes from naive and mCMV-infected (7 days) C57BL/6 mi
ecipients were stimulated with an equal number of irradiated EL-4
rradiated EL-4 cells that were not loaded with peptide (no sti
ncorporation. Mean and standard deviation for each group are show
ecipients of 30  106 amotosalen-treated splenocytes (Rx-30m) 17
late-bound anti-CD3 mAb for 4 days, and 100 000 splenocytes fr
s positive controls. After 4 days of culture, the cells were pulsed wit
as determined by the outer diameter measured at 595 nm (C). Rxytes. p
76An orderly pattern of BM-derived thymopoiesis
as observed in the mice that received amotosalen-
reated splenocytes, including thymic intermediates
CD4 CD8; Figure 6B). In contrast, these mice had
nly rare thymic intermediates derived from the amo-
osalen-treated splenocytes, thus indicating that ex-
ansion of amotosalen-treated T cells after BMT is
ikely to be thymus independent. Infusion of untreated
plenocytes resulted in thymopoiesis from both the
onor marrow and donor splenocytes. Thus, amoto-
alen treatment largely abolished lymphoid progenitor
ell activities in the donor splenocytes, although these
nimals displayed greater BM-derived thymopoiesis
han recipients of identical numbers of untreated
plenocytes and mCMV infection.
ISCUSSION
DNA-targeted photochemical treatment of allo-
eneic donor lymphocytes with amotosalen limits the
ted splenocytes. Amotosalen-treated and untreated T cells were
1, Thy1.1, and CD8, as well as the HGIRNASFI/H-2Db tetramer.
prepared similarly (A). Isolated splenocytes (100 000) from BMT
ded with mCMV peptide. Control wells contained splenocytes and
n). After 4 days, proliferation was measured by [3H]thymidine
onor spleen–derived CD45.1 cells were FACS-sorted from BMT
after transplantation. A total of 100 000 cells were stimulated with
T recipients of 1  106 untreated splenocytes (Cx-1m) were used
ylthiazoletetrazolium, and incorporated methylthiazoletetrazolium
tes amotosalen treated; Cx, untreated.len-trea
CD45.
ce were
cells loa
mulatio
n (B). D
0 days
om BM
h methroliferation of donor T cells in vitro and has been
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Effects of Amotosalen-Treated T Cells In Vivo
Bsed to promote BM engraftment with a limited risk
f GVHD in BMT recipients [16,26]. Using the
57BL/6 3 F1 murine BMT model with concomi-
ant mCMV infection, we recently extended these
ndings and reported the following. First, 90% to
00% of BMT mice survive if they do not receive
CMV infection or donor splenocytes. Second,
CMV infection (5  104 plaque-forming units) of
MT mice in the absence of splenocyte infusion pro-
uces 85% to 100% mortality by day 30. Thus,
ithout adoptive immunotherapy, mCMV infection is
lmost universally lethal in this model. Third, adop-
ive transfer of 30  106 untreated splenocytes to
MT mice (in the absence of mCMV infection) pro-
uces 100% mortality by day 35. In contrast, the
ame number of amotosalen-treated cells leads to
5% mortality up to day 80. These data showed
hat infusion of untreated donor splenocytes leads to
niversally lethal GVHD in this model and that this
an be prevented by amotosalen pretreatment of the
plenocytes before infusion. Fourth, most impor-
antly, amotosalen-treated lymphocytes retain potent
ntiviral activity in mCMV-infected BMT mice, on
he basis of reductions in mortality from mCMV dis-
ase, reductions in viral loads, and persistence of do-
or spleen–derived anti-mCMV CTLs [17]. Although
he splenocyte preparations contained approximately
0% CD3 T cells and although we have shown that
igure 6. Amotosalen-treated splenocytes promote donor marro
ransplantation from the designated BMT recipients. Cells were stai
D4 and CD8 T cells. A, The overall mean chimerism per thym
roup except for Cx-10m recipients, for which 3 mice were used.
plenocytes. Rx indicates amotosalen treated; Cx, untreated.nti-mCMV CTLs in the preparations survive and m
B&MTetain antiviral activity after amotosalen treatment
17], we have not yet ruled out the contribution of a
inor cell population to control of mCMV infection
n this model. Thus, amotosalen pretreatment effec-
ively dissociates the GVHD and antiviral activities of
onor splenocytes: treated splenocytes prevent other-
ise lethal mCMV disease without causing GVHD.
hese ﬁndings and the accompanying observation
hat amotosalen-treated T cells persisted after infu-
ion in vivo led us to investigate the effects of adoptive
mmunotherapy with amotosalen-treated donor sple-
ocytes on long-term reconstitution of antiviral im-
unity in MHC-mismatched BMT recipients.
There are 2 major ﬁndings of these investigations.
irst, amotosalen-treated T cells persist and retain long-
erm functional antiviral activity after infusion into BMT
ecipients. Although some surviving T cells reacquire
roliferative capacity, likely by repairing amotosalen
ross-links, there is no evidence of chronic GVHD.
econd, compared with recipients of untreated T cells,
MT mice that received amotosalen-treated cells
howed signiﬁcantly improved lymphoid reconstitution
rom donor BM–derived hematopoietic progenitors.
hese ﬁndings indicate that adoptive immunotherapy
ith amotosalen-treated lymphocytes can limit immune
eﬁciency after BMT by providing functional donor T
ells immediately after transplantation and by accelerat-
ng engraftment of the lymphoid system by donor he-
ived thymopoiesis. Thymocytes were harvested 4 months after
th mAbs for CD45.1 and Thy1.1, in combination with mAbs for
Representative FACS dot plots. Five to 6 mice were used in each
t t test; P 
 .05 as compared with recipients of 10  106 treatedw–der
ned wi
us. B,
*Studenatopoietic progenitors. In this respect, our ﬁndings
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1iffer from those of Arber et al. [27], who demonstrated
hat protection against lethal mCMV infection can de-
elop after adoptive transfer of common lymphoid pro-
enitors but did not test for antiviral activity sooner than
4 days after BMT.
Although mCMV-infected recipients of 3  106
motosalen-treated versus untreated splenocytes showed
imilar survival and weight gain, there are quantiﬁable
ifferences between the groups. For example, recipi-
nts of 3  106 pretreated splenocytes had more
M-derived lymphocytes in their spleens (Figure 2
nd Table 1), including slightly higher numbers of anti-
CMV CTLs (Figure 4C), and improved thymopoiesis
rom BM-derived progenitors (Figure 6). Additionally,
t is important to note that almost all mice receiving 3
o 30  106 amotosalen-treated splenocytes survived
ast 4 months and were available for analysis. Surviv-
ng mice gained weight appropriately without evi-
ence of GVHD. By comparison, there was a much
maller therapeutic window for mice receiving un-
reated splenocytes in this study. Infusion of untreated
plenocytes was effective only over the narrow range
f 1 to 3  106 cells. Furthermore, mice that survived
fter infusion of 10  106 and 3  106 untreated
plenocytes had evidence of GVHD. The group re-
eiving 10  106 had rufﬂed fur and reduced weight
ain, whereas mice receiving 3  106 untreated cells
ad small ﬁbrotic spleens containing few lymphocytes
Figure 2). Thus, compared with the narrow thera-
eutic window for untreated splenocytes, amotosalen
retreatment is advantageous in that it expands the
ffective range of lymphocyte doses for adoptive im-
unotherapy. The broad therapeutic range for amo-
osalen-treated lymphocytes may allow the use of mul-
iple escalated lymphocyte infusions to control viral
nfections with minimal risks that the accumulated
ells would produce GVHD.
Analysis of lymphocytes in the spleens of BMT re-
ipients 4 months after transplantation showed that ap-
roximately 6% to 10% of T cells were derived from the
 106 or 10  106 amotosalen-treated splenocytes
containing 0.6-2  106 donor T cells) infused at the
ime of transplantation (Table 1). Thus, the number of
cells derived from the amotosalen-treated splenocytes
as approximately equal to that present in the original
plenocyte graft. Because the spleen contains approxi-
ately10% of all T cells in the body (M.S.H., unpub-
ished data), these data imply that amotosalen-treated
onor T cells expanded by an average of approximately
0-fold after transplantation. The phenotype of surviv-
ng donor T cells was primarily (80%-90%) that of
emory CD8 T cells: CD3 CD8 CD44hi/int
D62L [28] (Figure 4, A and B). The surviving amo-
osalen-treated donor T cells were functional, as illus-
rated by production of IFN- in response to mCMV
ntigen exposure (Figure 4). Quantitation of anti-
CMV CTLs by ICS and tetramer staining produced w
78omparable results of 1 to 3.5  104 antigen-speciﬁc
onor spleen–derived CD8 T cells per spleen, on av-
rage, in recipients of amotosalen-treated splenocytes.
hus, a functional population of donor memory CD8
cells survives amotosalen treatment and persists in
HC-mismatched BMT recipients, thus resulting in
ong-term transfer of antigen-speciﬁc immunity without
VHD [19]. Survival seems to be dependent in part on
oncomitant mCMV infection, on the basis of nearly
ndetectable levels of anti-mCMV CTLs in uninfected
MT recipients.
The polyclonal TCR V repertoire of donor
pleen–derived T cells (Figure 3) argues against selective
urvival of a small oligoclonal population of pretreated T
ells and suggests the presence of T cells reactive to
ther antigens. Despite the polyclonality of persisting
onor T cells, these mice did not experience GVHD,
hus indicating that alloreactive donor T cells were ei-
her eliminated or inactivated after amotosalen pretreat-
ent. This illustrates a signiﬁcant difference between
he use of amotosalen-treated lymphocytes for adoptive
mmunotherapy and the earlier approach of using anti-
iral CTL clones expanded in vitro [8]. Transfer of
road-spectrum polyclonal immunity with amotosalen-
reated lymphocytes may be particularly effective against
iral mutants that do not express immunodominant
pitopes and can evade adoptively transferred CTL
lones with narrow antigen speciﬁcity [29].
Amotosalen-pretreated T cells, which do not pro-
iferate immediately after treatment [16,17], survived
or at least 4 months in vivo at high levels. Two
pproaches were used to demonstrate that they had
egained proliferative capacity after infusion. First,
ntigen-speciﬁc donor spleen–derived CD8 T
ells proliferated in response to mCMV peptide
oaded on EL-4 cells. Second, FACS-sorted donor
pleen–derived T cells proliferated in response to
ntigen-nonspeciﬁc stimuli (Figure 5). These ﬁnd-
ngs, along with evidence for a net 10-fold expansion
f amotosalen-treated donor T cells, likely indicate
hat pretreated donor T cells have repaired their DNA
ross-links. This process may possibly be due to co-
xisting viral infection or other in vivo stimuli, such as
nterleukin 2 and lipopolysaccharide, mainly produced
rom the intestines of irradiated recipients [30].
Although proliferation of mature pretreated
cells may in part explain the long-term persistence
f a polyclonal donor T-cell population, it is also
ossible that some of these cells had developed from
ymphoid progenitors among the pretreated spleno-
ytes. However, FACS analysis of thymocytes from
MT recipients clearly shows that amotosalen pre-
reatment largely abolishes thymus-dependent T-cell
xpansion (Figure 6). In contrast to recipients of un-
reated splenocytes, in which donor spleen–derived
D4 CD8T-cell progenitors were prevalent, there
as a complete absence of these donor spleen–derived
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Effects of Amotosalen-Treated T Cells In Vivo
Bhymic (common lymphoid) progenitors in recipients
f amotosalen-treated cells.
BM-derived immune reconstitution was signiﬁ-
antly better in recipients of amotosalen-treated ver-
us untreated splenocytes. Although there were no
igniﬁcant differences in donor spleen–derived or
ost-derived CD3 T cells between mice that re-
eived 3 to 10  106 amotosalen-treated splenocytes
r 3  106 untreated splenocytes, recipients of amo-
osalen-treated donor splenocytes had 3 to 4 times
ore CD3 T cells derived from donor BM than did
ecipients of untreated splenocytes. Improved BM-
erived lymphoid reconstitution is reﬂected in thymic
ymphoid development, including the presence of
arge numbers of BM-derived CD4 CD8 T-cell
rogenitors (Figure 6B).
The effects of amotosalen-treated splenocytes on
M lymphopoiesis are unlikely to be due to abroga-
ion of graft rejection (because in the parental 3 F1
odel there is no graft rejection vector) or to the
bility of pretreated splenocytes to directly promote
hymopoiesis. Rather, we favor the hypothesis that the
educed GVHD in BMT mice that received amoto-
alen-treated cells, as compared with untreated cells
Figure 1), provides an improved environment for BM-
erived lymphoid reconstitution. In the presence of
CMV infection, BM-derived thymopoiesis is reduced
n approximate proportion to the degree of GVHD
amotosalen-treated-10m  amotosalen-treated-3m 

ntreated-3m 
 untreated-10m). However, in the ab-
ence of mCMV infection and GVHD (amotosalen-
reated-30m/no mCMV), lower levels of thymopoiesis
re observed. Thus, mCMV infection may also have
n important effect on thymopoiesis, which we have
tarted to investigate. A role for GVHD is consistent
ith previous investigations demonstrating that
hronic GVHD inhibits thymopoiesis and causes thy-
ic dysfunction [31]. GVHD also induces thymic
ysplasia associated with thymic involution, depletion
f cortical and medullary thymocytes, epithelial cell
estruction, and loss of Hassall bodies, which collec-
ively result in T-cell lymphopenia, immunodeﬁ-
iency, and a failure of negative selection of poten-
ially autoreactive T cells [32-36]. Thus, reducing
VHD through the use of amotosalen-treated
plenocytes likely protects thymic function and sup-
orts the generation of BM-derived T cells.
In this experimental model, splenocytes were iso-
ated from donor mice that had recovered from sublethal
CMV infection 2 to 4 months earlier. The donors had
ompletely cleared active mCMV infection, and antiviral
TLs were present at signiﬁcantly lower levels than at
eak infection (data not shown), consistent with contrac-
ion to a long-term stable memory CTL population such
s is seen after experimental lymphocytic choriomenin-
itis virus infection [28]. Thus, this approach is likely to
e effective clinically by using CMV-seropositive donors
B&MTith remote infections, where anti-CMVCTLs can rep-
esent 4% of the peripheral CD8 T-cell population
n the absence of acute infection [37]. Because 60% to
0% of the population is seropositive, this method
hould be broadly applicable.
In summary, amotosalen-treated polyclonal donor
plenocytes persist long-term after infusion into MHC-
ismatched BMT recipients and protect against lethal
CMV infection. Pretreated cells have a memory phe-
otype and remain functional on the basis of IFN-
xpression after stimulation. Despite the observation
hat these cells regain proliferative capacity, they do not
nduce clinically detectable GVHD. It is interesting to
ote that adoptive immunotherapy with amotosalen-
reated splenocytes leads to improved thymopoiesis and
mmune reconstitution by BM-derived progenitors as
ompared with the use of untreated lymphocytes. Al-
hough we have shown that the administration of amo-
osalen-treated donor splenocytes at the time of alloge-
eic TCD BM eliminates early viral disease [17], this
pproach should also prevent late viral disease because
retreated T cells persist for longer than 4 months and
ccelerate donor BM–derived immune reconstitution.
hus, this is a potentially powerful approach to reduce
he window for opportunistic infections and disease re-
apse after transplantation. The use of amotosalen-
reated polyclonal donor T cells would be signiﬁcantly
ore rapid and less expensive than current approaches
nvolving the isolation and expansion of CMV-speciﬁc
-cell clones [8].
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